These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28557129)

  • 1. Recreational stimulants, herbal, and spice cannabis: The core psychobiological processes that underlie their damaging effects.
    Parrott AC; Hayley AC; Downey LA
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28557129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation.
    Parrott AC
    Hum Psychopharmacol; 2015 Jul; 30(4):213-24. PubMed ID: 26216554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs.
    Parrott AC
    Brain Sci; 2018 Mar; 8(3):. PubMed ID: 29533974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
    Parrott AC; Milani RM; Parmar R; Turner JD
    Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study on the sub-acute effects of mephedrone on mood, cognition, sleep and physical problems in regular mephedrone users.
    Homman L; Seglert J; Morgan MJ
    Psychopharmacology (Berl); 2018 Sep; 235(9):2609-2618. PubMed ID: 29946859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.
    Parrott AC; Milani RM; Gouzoulis-Mayfrank E; Daumann J
    J Neural Transm (Vienna); 2007; 114(8):959-68. PubMed ID: 17520319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosis associated with acute recreational drug toxicity: a European case series.
    Vallersnes OM; Dines AM; Wood DM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; ; Dargan PI
    BMC Psychiatry; 2016 Aug; 16():293. PubMed ID: 27538886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational 'ecstasy'.
    Parrott AC
    Behav Pharmacol; 2016 Dec; 27(8):649-658. PubMed ID: 27681116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
    Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects.
    Parrott AC; Downey LA; Roberts CA; Montgomery C; Bruno R; Fox HC
    J Psychopharmacol; 2017 Aug; 31(8):959-966. PubMed ID: 28661257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDMA, cortisol, and heightened stress in recreational ecstasy users.
    Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
    Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland.
    Liakoni E; Dolder PC; Rentsch K; Liechti ME
    Swiss Med Wkly; 2015; 145():w14166. PubMed ID: 26218967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of multitasking on psychological stress reactivity in recreational users of cannabis and MDMA.
    Wetherell MA; Atherton K; Grainger J; Brosnan R; Scholey AB
    Hum Psychopharmacol; 2012 Mar; 27(2):167-76. PubMed ID: 22389081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 18. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug addiction and withdrawal].
    Tacke U; Kuoppasalmi K; Airaksinen M
    Duodecim; 1998; 114(10):1003-17. PubMed ID: 11524775
    [No Abstract]   [Full Text] [Related]  

  • 20. New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.
    Sutherland R; Peacock A; Whittaker E; Roxburgh A; Lenton S; Matthews A; Butler K; Nelson M; Burns L; Bruno R
    Drug Alcohol Depend; 2016 Apr; 161():110-8. PubMed ID: 26880592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.